Evidence map›Paper›PMID 37219795›Full record

ReviewInfectious diseases and therapy2023

Determinants of Meningococcal Vaccination Coverage and Adherence: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit.

Oscar Herrera-Restrepo, Yuting Kuang, John D'Angelo, Rafik Bekkat-Berkani, Diana E Clements, Jennifer Uyei

Open access · goldAbstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Oscar Herrera-RestrepoGSK, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA, 19104, USA. oscar.x.herrera-restrepo@gsk.com.ORCID http://orcid.org/0000-0001-8193-999X
Yuting KuangIQVIA, San Francisco, USA.ORCID http://orcid.org/0000-0003-2756-4175
John D'AngeloGSK, Philadelphia, USA.ORCID http://orcid.org/0000-0002-1350-4270
Rafik Bekkat-BerkaniGSK, Rockville, USA.ORCID http://orcid.org/0000-0003-0683-6055
Diana E ClementsGSK, Philadelphia, USA.ORCID http://orcid.org/0000-0002-2410-8951
Jennifer UyeiIQVIA, San Francisco, USA.ORCID http://orcid.org/0000-0003-4397-8554
GlaxoSmithKline (United States) · USIQVIA (United States) · USFMC (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a targeted literature review to understand the determinants of meningococcal serogroups A, C, W, and Y (MenACWY) and meningococcal serogroup B (MenB) vaccination coverage and adherence to vaccination schedules in the USA, and to identify evidence to support improvement of MenACWY and MenB vaccination coverage and adherence in older adolescents. Sources published since 2011 were considered, with sources published since 2015 given preference. Out of 2355 citations screened, 47 (46 studies) were selected for inclusion. Determinants of coverage and adherence ranging from patient-level sociodemographic factors to policy-level factors were identified. Four determinants identified were associated with improved coverage and adherence: (1) well-child, preventive, or vaccination-only appointments (particularly for older adolescents); (2) provider-initiated, provider-driven vaccine recommendations; (3) provider education about meningococcal disease and vaccine recommendations; and (4) state-level school-entry immunization policies. This robust review of the literature sheds light on the continued low MenACWY and MenB vaccination coverage and adherence among older adolescents (16-23 years of age) compared with that of younger adolescents (11-15 years of age) in the USA. The evidence supports a renewed call to action by local and national health authorities and medical organizations urging healthcare professionals to implement a healthcare visit for 16-year-olds and focus on vaccination as a key component of the visit.

Indexed as

AdolescentsInvasive meningococcal diseaseMenACWYMenBYoung adults

Identifiers

PMID37219795
PMCPMC10203675
OpenAlexW4377564621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.